"Lab on a chip" test for diabetes and cardiovascular disease

A Colorado State University chemistry professor has developed a way to rapidly test blood for signs of diabetes and cardiovascular disease - methods that could save patients and physicians significant time and money.

Using a combination of chemistry and engineering, Charles Henry and his team apply patterning techniques developed by the semiconductor industry to inexpensively fabricate diagnostic devices. The Henry group developed a simple means of detecting biomarkers within these devices through electrochemical detection.

With this advancement, small sample volumes could be analyzed cheaply, rapidly and with a high degree of sensitivity. Blood from a simple finger prick instead of a blood draw can be analyzed for markers of health conditions such as diabetes and cardiovascular disease.

Henry and his team have created a company called Advanced MicroLabs LLC to commercialize the invention, and Advanced MicroLabs has licensed the technology from Colorado State University Research Foundation. The company is focusing on the growing market called "lab on a chip" - a field that promises to perform complicated diagnostic analyses on a small format, rapidly and inexpensively. Analyses that once required large and expensive benchtop equipment can now be performed in a format that fits into one's hand.

"Strides have been made toward improving behavioral patterns that put people at risk of diabetes and cardiovascular disease, but there's still a need to develop methods to detect the onset of disease at the earliest possible stage," Henry said. "Advanced MicroLabs is developing technology for rapid detection of signs of diabetes and cardiovascular disease that will be inexpensive and require very small samples."

According to the American Diabetes Association, 20.8 million children and adults in the United States, or 7 percent of the population, have diabetes. According to the World Health Organization, the number of diabetics will double by 2025.

Two government agencies have already embraced the new technology by supporting preliminary research that aims to bring the patent-pending technology to the marketplace so patients may benefit. The National Science Foundation has provided $600,000 in funding through the Small Business Innovative Research grant program for diabetes-related work. The National Institutes of Health has provided an additional $100,000 grant for cardiovascular disease work. In both cases, the work is done in a collaborative effort between Advanced MicroLabs and Henry's laboratory at Colorado State University.

The company aims to develop the next generation of diabetic monitoring devices using its lab-on-a-chip technology. Using an integrated microchip, diabetics could someday obtain instant, historic information about glucose levels from the multiple daily measurements they already take as well as markers of long-term glucose regulation and well-known complications.

"Someday, such a test might also provide a more complete analysis for not only diabetes, but also for common complications," said Jeff Myers, a Loveland consultant and a diabetic who is working with Advanced MicroLabs.

"Diabetes has become a major health issue in the United States and around the world, and it's only expected to get worse because of lifestyle changes people are making," said Dale Willard, co-founder of the company, senior research scientist and the company's only full-time employee.

Additionally, a microchip developed by Advanced MicroLabs measures homocysteine, which is an amino acid that has been linked to cardiovascular disease. Existing methods for measuring homocysteine are costly and can be performed only in a clinical laboratory.

"Our goal is to refine the technology invented at Colorado State and turn it to an effective tool for patients and doctors for regular checkups," said Willard, who obtained his doctoral degree in chemistry from Colorado State in 1999. "We translate the technology into real-world solutions."

Lab-on-a-chip can be expanded into many other applications, and Henry expects to collaborate with scientists in other colleges at Colorado State University on such projects as testing aerosols or small particulates in the air. He's working closely with Jeff Collett in the College of Engineering's Department of Atmospheric Science and a small California company to explore atmospheric applications.

Henry has been an assistant professor of chemistry at Colorado State since 2002. Previously he worked as assistant professor at Mississippi State University. He obtained his bachelor's in chemistry from Missouri Southern State College and his doctoral in analytical chemistry from the University of Arkansas.

As part of Colorado's economic development plan, Gov. Bill Owens recently signed House Bill 1360 into law to better use state resources while at the same time seeding state-grown economic development in the biosciences.

"We are hoping to ride this wave of support for developing locally grown technologies within our state," Willard said. "We have a technology that could one day benefit the greater good but is already benefiting Colorado State University and the Colorado economy."

Grants awarded to Advanced MicroLabs have supported research within the company as well as original research within the Colorado State University chemistry department. Additionally, Advanced MicroLabs employs three scientists and four undergraduate students. Undergraduates earn money to support their ongoing education and gain experience in a commercial laboratory.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes medication shows promise in reducing alcohol use